

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
FIRST PATIENT ENROLLMENT COMPLETED IN
THE PHASE III CLINICAL TRIAL OF OT-211

This announcement is made by Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that the phase III clinical trial of OT-211 (AR-15512) in the PRC has enrolled its first patient. OT-211 (AR-15512) is a 0.003% concentration eye drop formulation and the first TRPM8 agonist approved by the U.S. Food and Drug Administration (“**FDA**”) for the treatment of dry eye disease (“**DED**”). The successful enrollment of the first patient marks an important milestone in the clinical development of OT-211 in China, and demonstrates the Group’s commitment to advancing innovative therapies for DED patients.

Alcon Inc. (together with its subsidiaries, “**Alcon Group**”), the global leader in eye care with complementary businesses in surgical and vision care, developed the 0.003% concentration eye drop formulation of AR-15512 and completed one phase IIb and three phase III clinical trials. OT-211 (AR-15512) was approved by the FDA on May 28, 2025 for the treatment of the signs and symptoms of DED. The Group, after the strategic cooperation with Alcon Group in October 2024, obtained an exclusive license from the Alcon Group to develop, make, have made, import, export and sell OT-211 (AR-15512) in Chinese Mainland.

Cautionary Statement: The Company cannot guarantee that it will be able to successfully develop or ultimately commercialize OT-211 (AR-15512). Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumention Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, March 30, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.